As we are all painfully aware, prostate cancer is immunologically "cold." This means the immune system cannot be coaxed into attacking it. The one exception is Provenge.
BiTEs (Bispecific T-cell Engagers) are in clinical trials. BiTEs are medicines that have one "hook" that connects to a cancer cell antigen (like PSMA) and another hook that brings a T-cell in to kill the cancer cell.
Regeneron cancelled a clinical trial for REGN5678 after 2 men died from immune-related deaths. Last year, Harpoon canceled its trial after early results were toxic and failed to demonstrate efficacy.
fiercebiotech.com/biotech/r...
fiercebiotech.com/biotech/h...
There are still several more in trials.